Everyone we’ve sought evidence from has done so willingly and co-operatively. We’ve heard a very diverse range of views and learned a great deal about what happened and how key decisions were made. People have been reflective of what went well, and what did not go well and have constructively suggested to us what they think the lessons are. We have also requested key decision-making documents, data and advice to ensure we can assess the basis and processes used in decisions taken at the time – so we can make recommendations to improve that in response to a future pandemic.
Given that our engagements have not been public, we’ve done several things to ensure people have visibility of our work. Our website lists the people and organisations we have met with. Regular newsletters and videos profile people and organisations that we have engaged with, and their reflections on the issues they wanted to bring before the inquiry. We’ve proactively run a campaign to encourage public input into the inquiry and gone to great lengths to reach people who might not otherwise have a voice.
The Government is currently reviewing our terms of reference or the parts of the pandemic response we are tasked with looking at. Our current terms of reference are broad enough to allow us to look at a wide range of Covid-19 related topics, like mandates and lockdowns and social impacts such as the impact on education and mental health, but we recognise there may be specific topics that people would like considered and which could be included, or clarified. We’ve supported this by consulting with the New Zealand public, on the Government’s behalf, about a proposed expansion.
It would be useful to clarify to what extent vaccine effectiveness is considered as part of the Inquiry. We know that the use of vaccines is a really important topic for many people. It’s difficult for us to consider vaccine mandates and passes, and the overall elimination strategy without also considering issues about vaccine effectiveness. By this, we mean how effective the vaccine is at preventing death, preventing hospitalisation and preventing transmission. For example, the ethical case for – say – vaccine mandates is stronger if vaccines also stop transmission.
We are looking closely at what happened, and what might happen in a future pandemic, taking into account a range of perspectives. For example, we are looking at the decisions that were made from the point of view of those with high health needs, like disabled people, versus the wider community’s desire to get back to some sense of normal life, and how best to strike the right balance between these two needs. This involves asking hard questions about the effectiveness and impacts of New Zealand’s Covid-19 response.
We then identify what we can learn from our findings, to prepare for, respond to, and recover from the next pandemic. To help us arrive at a lesson, we are approaching it by first putting ourselves in the shoes of the decision maker at the time, and asking questions like, “did they have all the information they should have had? And if not, why not? And what are the lessons here for better systems next time around?”.
Secondly, we have learnt from Covid-19 which measures attracted widespread support and which proved highly divisive and risked undermining support in the fight against the virus. Now we have the benefit of hindsight and lessons about these long-term impacts, we can carry them forward to assist decision-making in the next pandemic.
Our Covid-19 Royal Commission is making good progress. If we receive revised terms of reference – probably mid-year – from the Government, we will take stock, and adjust our processes and deliberations as required. This may include further engagements and consultation. And we will update the New Zealand public on changes to our processes as soon as we can.
Professor Tony Blakely is chair of the Royal Commission of Inquiry into Covid-19
